Latest News and Press Releases
Want to stay updated on the latest news?
-
– Closed enrollment for olinciguat Phase 2 STRONG SCD study for sickle cell disease; topline data readout expected Q3 2020 – – Closed enrollment for IW-6463 translational pharmacology...
-
– Results in 110 subjects demonstrate favorable safety, CNS pharmacokinetics, and evidence of target engagement – – Study underway in elderly subjects to further assess cerebral blood flow and...
-
CAMBRIDGE, Mass., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase...
-
– Study did not reach statistical significance on primary endpoint – – Positive trends on primary and secondary endpoints indicate profile that merits further investigation – – Company intends to...
-
– Study in HFpEF patients did not meet primary endpoint; company discontinuing development of praliciguat in HFpEF – – Conference call to be held at 8:30 a.m. ET today – CAMBRIDGE, Mass., Oct. ...
-
CAMBRIDGE, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for...
-
CAMBRIDGE, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase...
-
– Two praliciguat Phase 2 studies for diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF) on track for data readouts in Q4 2019 – – Phase 2 study of olinciguat in sickle...
-
– Series of preclinical studies provide further rationale for study of IW-6463 as a potential treatment for neurodegenerative diseases – – Preclinical data provide insights into...
-
– In preclinical study, treatment with company’s investigational sGC stimulator olinciguat was associated with improved blood flow and reduced inflammation in a model of sickle cell disease – – New...